Market news

PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.

VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.

PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.

VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.

Detailed price information for Novartis Ag ADR (NVS-N) from The Globe and Mail including charting and trades.

PPH targets drugmakers exclusively with higher returns but steeper costs, while XLV diversifies across medical equipment and providers at a fraction of the fee.

The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The choice comes down to whether to lean into pharma-driven returns or take a broader approach to global healthcare.

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity.